Cancer drug start-up Peloton raises $18M
This article was originally published in Scrip
Executive Summary
Peloton Therapeutics, a Dallas, Texas-based early-stage small-molecule cancer drug company, has come out of stealth mode. It has announced that it raised $18 million in a series A financing for development on three in-licensed programmes from the University of Texas Southwestern Medical Center. This follows an $11 million grant from cancer research funds provided by the state of Texas.
You may also be interested in...
Merck Buys Peloton On Eve Of IPO, Expands Kidney Cancer Portfolio
Investors in Peloton, which has the only clinical-stage HIF-2α inhibitor, will get back 3.5 times the $304m in venture capital invested in the firm via the $1.1bn that Merck is paying up front. With all $1.15bn in additional milestone fees, the return could grow to 7.2x.
VC Roundup: Early-Stage Funding Slips Again In Third Quarter, Plus 15 New Financings
Early-stage venture capital funding continues to decline, but corporate VC dollars and other sources of cash are emerging to fund startups. Also, biopharma companies raised $436.3m in 15 recent financings.
ChemoCentryx cuts price to get $45M IPO away
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).